Literature DB >> 1788981

N-dealkylation of tertiary amides by cytochrome P-450.

L R Hall1, R P Hanzlik.   

Abstract

1. N-Methyl-N-alkyl-p-chlorobenzamides (alkyl = Me, Et, nPr, nBu, PhCH2, isoPr and cylcoPr) underwent mono-N-dealkylation exclusively with phenobarbital-induced rat liver microsomes; with each compound both demethylation and dealkylation occurred. 2. The time-courses showed bilinear kinetics, but there was no evidence for general suicide-substrate activity with the cyclopropyl amide, and product ratios did not vary with time. 3. The demethylation/dealkylation ratio varied from 0.3 to 2.0 among the primary alkyl groups but was ca. 40 when the alkyl group was isoPr or cylcoPr. Dealkylation of the benzyl substituent was 2-3 times more favourable than for any other primary alkyl group. Despite wide variations in the demethylation/dealkylation ratios, at near-saturating concentrations of substrates the rates of total oxidation (demethylation plus dealkylation) varied little across the entire series. 4. The results of this study are consistent with a kinetic mechanism involving significant commitment to catalysis, substituent-induced metabolic switching at the product-determining step, a non-catalytic step which is partly rate-limiting in turnover, and a chemical mechanism involving H-atom abstraction as opposed to electron abstraction.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1788981     DOI: 10.3109/00498259109039553

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  2 in total

1.  Identification of major urinary metabolites of the catechol-O-methyltransferase inhibitor entacapone in the dog.

Authors:  T Wikberg; P Ottoila; J Taskinen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Oct-Dec       Impact factor: 2.441

2.  Metabolite profiles of two [14C]-labelled catechol O-methyltransferase inhibitors, nitecapone and entacapone, in rat and mouse urine and rat bile.

Authors:  T Wikberg; A Vuorela
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Apr-Jun       Impact factor: 2.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.